Our data claim that a rise in on-target off-tumor toxicity of daratumumab by ricolinostat is improbable in T cells and NK cells [32], even though regulatory T cells remain vunerable to daratumumab-mediated depletion

Our data claim that a rise in on-target off-tumor toxicity of daratumumab by ricolinostat is improbable in T cells and NK cells [32], even though regulatory T cells remain vunerable to daratumumab-mediated depletion. amounts suggesting the fact that upregulation of Compact disc38 expression on MM cells by HDAC6 inhibitors is a class effect. This proof-of-concept illustrates the potential benefit of combining HDAC6 inhibitors and CD38-directed immunotherapy for MM treatment. Subject terms:Combination drug therapy, Myeloma, Immunotherapy == Introduction == Multiple myeloma (MM) is a plasma cell neoplastic disease with a median overall survival of 4.47.1 years that often runs an aggressive and incurable course [1]. The treatment of MM has improved remarkably over the last 15 years because of the development of novel agents such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) [13]. Nevertheless, MM remains an incurable disease as patients continue to relapse upon treatment. It is therefore necessary to develop more efficient MM therapies, especially for people who have relapsed after treatment with PIs and IMiDs [4,5]. For these patients, the anti-CD38 monoclonal antibody (mAb) daratumumab was first approved in 2015 as a single agent therapy [6,7]. CD38 is highly Paullinic acid and ubiquitously expressed on MM cells and at low levels on normal lymphoid and myeloid cells [8]. CD38 is a Paullinic acid transmembrane glycoprotein with ectoenzymatic activity in the catabolism of extracellular nucleotides [9]. Other functions include receptor-mediated adhesion by interacting with CD31 or hyaluronic acid, regulation of migration, and signaling events [10]. In patients with relapsed/refractory (R/R) MM, daratumumab monotherapy produces only a low rate of partial and complete remission (29.2%), and a limited median duration of response (7.4 months) [7,11]. Therefore, daratumumab is increasingly being used in combination with bortezomib/dexamethasone (dex) or lenalidomide/dex at first Paullinic acid relapse. Such combined treatment induces a complete response (CR) in a notable percentage of patients (19.2% with dex and 43.1% with lenalidomide/dex) [12,13]. More recently, daratumumab has also been approved as a third-line treatment in combination with Rabbit polyclonal to ARHGAP21 pomalidomide/dex (CR rate 17%) and as a first-line treatment in combination with bortezomib/melphalan/prednisolone (CR rate 43%) [14]. However, although combination therapies using daratumumab belong to the most potent regimens currently available, there are still relapsing or refractory patients [1214]. Clinical observations with daratumumab are that the expression of CD38 on pretreated MM cells correlates with efficacy and that patients with higher CD38 expression are more likely to respond [15]. Moreover, during daratumumab therapy, CD38 expression levels on MM cells decline thus favoring immune escape and disease progression [15]. These observations suggest that an increase in the density of CD38 molecules on MM cells is likely to improve response rates and response durability of daratumumab treatment, and prevent immune escape. Therefore, a great amount of research is being invested in defining agents that increase CD38 expression on MM cells and work synergistically with daratumumab. As part of this research, we have recently shown that panobinostat induces CD38 upregulation and augments the antibody-dependent cellular cytotoxicity (ADCC) of daratumumab [16]. Panobinostat is the only histone deacetylase (HDAC) inhibitor approved for myeloma treatment and non-selectively inhibits all HDAC isoforms. However, as panobinostat is associated with relevant toxicity, its clinical use is currently limited. In search of HDAC inhibitors with a more beneficial side effect profile than panobinostat, novel agents such as ricolinostat (ACY-1215) have been investigated. Ricolinostat is an orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Its efficacy was evaluated in a phase 1/2 trial as monotherapy and in combination with bortezomib and.